Testing to Prevent: Singapore’s New Subsidies for Hereditary Cancer Screening in 2026

Singapore is moving preventive care upstream by subsidising genetic testing for hereditary breast and ovarian cancer (HBOC) from December 2026, according to the Ministry of Health (MOH). For eligible Singapore citizen and permanent resident patients, the genetic test will be means-tested and subsidised by up to 70 per cent. Seniors from the Pioneer and Merdeka generations will qualify for additional subsidies on top of that. Patients can also use MediSave to cover remaining costs after subsidies, and those aged 60 and above may use Flexi-MediSave to further reduce out-of-pocket expenses.

MOH’s move responds to measurable inherited risk. About one in 150 Singaporeans carries a mutation in HBOC-associated genes, which MOH said significantly raises risk of developing breast and ovarian cancer. Among women with such gene variants, lifetime breast cancer risk can be up to 60 per cent, while ovarian cancer risk can be up to 50 per cent. MOH contrasted this with the general female population, where lifetime risks are up to 13 per cent for breast cancer and up to 2 per cent for ovarian cancer. In parliament, Health Minister Ong Ye Kung said the ministry expects over 2,000 individuals to be eligible for the HBOC genetic test annually.

What Happens After a Positive Result: Financing and Follow-up

Testing is only the first step. For those found to have a mutation, Ong said they will be offered suitable preventive interventions. He described these as typically including more frequent breast MRIs or mammograms, or oral medications, with patients deciding in consultation with their doctors. A minority may opt for surgical interventions. MOH also said the full suite of HBOC interventions, from genetic testing to follow-up treatment, has been assessed as clinically and cost-effective, and that further details on financing support will be released later in the year.

Beyond subsidised testing, MOH will extend MediShield Life coverage to selected risk-reducing surgical procedures for patients who test positive for HBOC. MOH noted that such preventive surgery is currently subsidised but not covered by MediShield Life or MediSave. Ong argued that, with advances in medical science, the boundary between preventive and curative care is increasingly blurred. He said that if a high-risk individual is unable to undergo a preventive mastectomy, she has a high chance of eventually needing cancer treatments, including a curative mastectomy to remove cancerous tissues. Separately, a report on the measures also stated that breast reconstruction is covered alongside the extension of MediShield Life and MediSave to cover preventive surgeries for HBOC.

This policy direction aligns with local evidence on access and uptake. A BMJ Open study in Singapore examined hereditary cancer genetic testing uptake and reported that its analysis suggests the potential value of financial subsidies in promoting equitable access to genetic testing, even with partial support. The study also noted that family history was significantly associated with increased likelihood of undergoing testing, and that uptake patterns were more similar in the presence of subsidies. Against that backdrop, the 2026 shift toward Singapore subsidised genetic testing for hereditary cancer aims to make risk identification and downstream management more accessible for those who meet clinical criteria and need earlier, more personalised prevention planning.